|
Total number
|
210
|
|
Females/males
|
149 (71 %)/61 (29 %)
|
|
Age (years)
|
Mean 14.4 (SD 3.40) Median 15.00 (Range 7–21)
|
|
Height (m)
|
Mean 1.60 (SD 0.15) Median 1.62 (Range 1.14–1.87)
|
|
Weight (kg)
|
Mean 52.8 (SD 15.9) Median 53.8 (Range 18.5–97.0)
|
|
BMI SDS a
|
Mean 0.4 (SD 1.17) Median 0.50 (Range −3.2–3.6)
|
|
Waist-to-height ratio (163 patients)
|
Mean 0.44 (SD 0.04) Median 0.43 (Range 0.35–0.62)
|
|
Tanner Stadium
|
121 (57.6 %) in Tanner Stage 5
|
|
JIA subgroup:
|
|
- Systemic
|
6 (2.9 %)
|
|
- Persisting Oligoarticular
|
65 (31 %)
|
|
- Polyarticular, RF negative
|
53 (25 %)
|
|
- Polyarticular, RF positive
|
8 (3.8 %)
|
|
- Psoriasis associated
|
21 (10.0 %)
|
|
- Enthesitis associated
|
56 (26.7 %)
|
|
- Undifferentiated
|
1 (0.5 %)
|
|
- Anti-Nuclear Antibodies (ANA) positive
|
32 (15.2 %)
|
|
- HLA-B27 positive
|
40 (19 %)
|
|
Treatment
|
|
- Methotrexate
|
40 (19 %)
|
|
- Biologics +/− Methotrexate:
|
142 (68 %)
|
|
either TNF-α inhibitors
|
130
|
|
or IL-6 receptor inhibitor
|
4
|
|
or T-cell co-stim inhibitor CTLA-4-Ig
|
8
|
|
- Solely by intra-articular injections
|
13 (6.2 %)
|
|
- None
|
10 (4.8 %)
|
|
- No information
|
4 (1.9 %)
|
|
Disease duration b in years
|
Mean 6.1 (SD 3,7) Median 5.2 (Range 0.5–17.3)
|
|
Complete remission off medication
|
4 (1.9 %)
|
